根治性放化疗期间磁共振成像可预测局部晚期宫颈癌肿瘤复发和患者生存:KROG 16-01多机构回顾性分析
多机构回顾性分析225例FIGO Ib2-IVa期宫颈鳞癌患者,在根治性放化疗期间行MRI评估肿瘤反应。MRI有反应组112例(49.7%),中位随访36.2个月,有反应组腹主动脉旁复发率和远处转移率显著低于无反应组,3年病因特异性生存率显著更高。
要点
- 225例局部晚期宫颈鳞癌患者放化疗期间MRI评估肿瘤反应,有反应者112例(49.7%)。
- 有反应组腹主动脉旁复发7.5% vs 无反应组12.4%(p=0.04),远处转移13.2% vs 27.6%(p=0.03)。
- 有反应组3年病因特异性生存率94.6% vs 无反应组81.1%(p<0.01)。
核心结论
- 使用FIGO分类的MRI早期肿瘤反应评估有效预测局部晚期宫颈癌的远处转移和疾病特异性生存。
研究设计与样本
- 多机构回顾性分析,纳入225例组织学确诊宫颈鳞癌、初诊盆腔MRI分期FIGO Ib2-IVa期患者。
- 放化疗开始后中位35天、近距离治疗前行放化疗后MRI,外照射中位剂量54Gy并每周顺铂同步化疗。
主要发现
- 225例中112例(49.7%)放化疗后MRI显示阳性反应,命名为有反应组。
- 中位随访36.2个月,有反应组腹主动脉旁复发率7.5% vs 无反应组12.4%(p=0.04)。
- 有反应组远处转移率13.2% vs 无反应组27.6%(p=0.03)。
- 有反应组3年病因特异性生存率94.6% vs 无反应组81.1%(p<0.01)。
- 多因素分析中,肿瘤大小(风险比1.91,95%置信区间1.07-3.43;p=0.028)和阳性MR反应(风险比1.75,95%置信区间1.06-2.27;p=0.045)为无复发生存的显著因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Definitive chemoradiotherapy (CRT) followed by brachytherapy is a standard treatment for locally advanced cervical cancer. During CRT, marked reduction of cervical tumor is often observed in magnetic resonance imaging (MRI). The primary aim of this study was to assess the association between tumor response in MRI using FIGO classification and clinical outcomes. METHODS: Multi-institutional data were retrospectively reviewed to identify the significance of MR tumor response on tumor recurrence and patient survival. 225 patients with histologically confirmed squamous cell carcinoma of the cervix, staged as FIGO Ib2-IVa on initial pelvic MRI, were included. Post-CRT MRI was performed median 35days after the beginning of CRT and before brachytherapy. A median 54Gy of external radiation was given with weekly cisplatin during CRT. RESULTS: 112 (49.7%) of the 225 patients showed a positive response in post-CRT MRI and were named the responsive arm. After a median follow-up time of 36.2months, the responsive arm had significantly lower para-aortic recurrence (7.5% vs. 12.4%; p=0.04) and distant metastasis (13.2% vs. 27.6%; p=0.03) rates than did the non-responsive arm. The responsive arm had significantly higher 3-year cause-specific survival rate (94.6% vs. 81.1%, p<0.01) than did the non-responsive arm. In the multivariate analysis, tumor size (hazard ratio, 1.91 and 95% confidence interval, 1.07-3.43; p=0.028) and positive MR response (hazard ratio, 1.75 and 95% confidence interval, 1.06-2.27; p=0.045) were significant factors for recurrence-free survival CONCLUSION: Early tumor response evaluation with MRI using FIGO classification effectively predicted distant tumor metastasis and disease-specific survival in locally advanced cervical cancer.
引用
- Lee SW, Lee SH, Kim J, et al. Magnetic resonance imaging during definitive chemoradiotherapy can predict tumor recurrence and patient survival in locally advanced cervical cancer: A multi-institutional retrospective analysis of KROG 16-01. Gynecol Oncol. 2017. PMID: 28935271. doi:10.1016/j.ygyno.2017.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。